Latest Publications | Neuroprotection | News | RGTA technology
Intra‑arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial Xavier Barreau1 · René Anxionnat2 · Olivier Heck3 · Igor Sibon4,5 · Charlotte Rosso6 · Catherine Oppenheim7 · Francisco Moniche8 · Frédéric Sedel9 · Franck Chiappini9 · Agnès Choppin9 · Martin Inizan9 · Denis Barritault9 · [...]
Neuroprotection | News
OPTIMIZATION OF EXTRACELLULAR VESICLES-BASED THERAPY IN THE TREATMENT OF ISCHEMIC STROKE Poster Session on the Friday 25th of April at 4:30PM at ISEV Congress in Vienna Ons BEN HADJ HASSEN1, Sarah RAZAFINDRAKOTO2, Jérôme TOUTAIN1, Isis BLANCHARD1, Viktoriia IVANOVA1, Charlène RENOULT1,3, Xavier LAFFRAY4, Minh-Bao HUYNH4, Carole BRUNAUD1, Karim BORDJI1, Gael LE [...]
Neuroprotection | News
OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]